Evaluating Adverse Events and Management Strategies in Foam Sclerotherapy: A Case Report of Sinus Venosus Atrial Septal Defect
Open Access
- 25 February 2025
- journal article
- Published by Hitit University in Hitit Medical Journal
- Vol. 7 (1) , 143-147
Abstract
Foam sclerotherapy (FS) is widely employed for minimally invasive varicose vein treatment. Despite contraindications in symptomatic right-to-left shunt cases like patent foramen ovale, routine pre-procedure transthoracic echocardiogram (TTE) screening isn't standard. This article discusses managing chest symptoms during FS in a young woman later diagnosed with an unknown sinus venosus atrial septal defect (SV-ASD). FS was administered to a 38-year-old female with symptomatic CEAP-1, who developed chest symptoms. Subsequent diagnosis revealed SV-ASD. Minimally invasive repair followed four weeks later. While FS is generally safe, it poses systemic adverse event risks, emphasizing vigilance in managing SV-ASD patients undergoing FS.Keywords
This publication has 9 references indexed in Scilit:
- Sclerotherapy in the treatment of varicose veinsDie Dermatologie, 2020
- Safety Concerns for Sclerotherapy of Telangiectases, Reticular and Varicose VeinsPharmacology, 2016
- Atrial septal defectsThe Lancet, 2014
- Complications of Foam SclerotherapyPhlebology: The Journal of Venous Disease, 2012
- Sclerotherapy of Varicose Veins with Polidocanol Based on the Guidelines of the German Society of PhlebologyDermatologic Surgery, 2010
- Toxicité cardiaque du polidocanol : rapport d’un cas et revue de la littératureJournal des Maladies Vasculaires, 2008
- Stroke after varicose vein foam injection sclerotherapyJournal of Vascular Surgery, 2006
- Patent Foramen Ovale and StrokeMayo Clinic Proceedings, 2004
- Preliminary Experience with a New Sclerosing Foam in the Treatment of Varicose VeinsDermatologic Surgery, 2001